Buspirone, formerly marketed under the brand name BuSpar®, is among the medications employed in the treatment of anxiety. Produced and distributed by the global pharmaceutical company Bristol-Myers Squibb, it gained FDA approval in 1986 and is frequently prescribed as an alternative to conventional anxiety medications for managing anxiety disorders or providing short-term relief from anxiety symptoms.
This medication can contribute to clearer thinking, relaxation, reduced worry, and enhanced participation in daily life. It may also alleviate jitteriness, decrease irritability, and address symptoms like insomnia, excessive sweating, and rapid heartbeats.
Originally developed in the 1960s and 70s as a medication for psychosis, buspirone, despite the discontinuation of the BuSpar brand name over a decade ago, is still informally referred to by this name when discussing the generic form.
BuSpar received FDA approval for treating anxiety disorders and providing short-term relief from anxiety symptoms. Additionally, it is employed off-label as an augmentation agent, used in conjunction with another medication, to address specific types of depression and mental health issues.
While demonstrated to be effective in alleviating anxiety symptoms, BuSpar was typically not the primary treatment choice. Instead, it was often prescribed when other anxiety medications, such as selective serotonin reuptake inhibitors (SSRIs) or benzodiazepines, proved ineffective or resulted in severe or persistent side effects.